Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Mar 7;14:1095487. doi: 10.3389/fphar.2023.1095487

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2023 Zeng, Huang, Zhang, Lv, Cheng, Zou, Han, Wang, Gong and Peng.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Dapagliflozin reduced the expression of renal fibrosis-related markers in HK2 cells stimulated by TGF-β1. (A) CCK8 was used to evaluate the toxicity of dapagliflozin to normal cells. (B, C) Western blot showing the expression of FN and α-SMA in HK2 cells in each group. (D) The ROS content in HK2 in each group. ***p < 0.001 TGF-β1 stimulated group compared with the control group; Values are means ± SD. ^### p < 0.001 dapagliflozin treatment group compared with TGF-β1 stimulation group; and p < 0.05 20 uM dapagliflozin treatment group compared with 40 uM dapagliflozin treatment group; and p < 0.01 20 uM dapagliflozin treatment group compared with the 40 uM dapagliflozin treatment group.